Poster

Evolution of AJICAP™ Technology

antibody

Ajinomoto Co. has developed an innovative direct chemical site-selective conjugation method intended for use with intact native antibodies. AJICAP™ technology is a novel platform for the site-selective conjugation of antibodies using a class of Fc-affinity compounds to install payload-compatible linkers to well-defined amino acid residue(s). The wide compatibility of the native antibody allows for well tolerated modifications (if required). With the broad drug-linker compatibility of AJICAP™ -- Azide as well as Thiol functionality can be introduced. The therapeutic window has been enhanced with improvements demonstrated in pharmacokinetic analysis and efficacy. AJICAP™ technology promotes a more straightforward manufacturing process with increased productivity and shorter conjugation reaction times. This poster series illustrates the AJICAP™ technology story.

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Ajinomoto Bio-Pharma Services